CastleKnight Management LP Sells 51,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CastleKnight Management LP lessened its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 23.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,400 shares of the company’s stock after selling 51,500 shares during the period. CastleKnight Management LP’s holdings in Teva Pharmaceutical Industries were worth $3,689,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in TEVA. Diversify Advisory Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after purchasing an additional 496 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after purchasing an additional 699 shares during the period. Townsquare Capital LLC grew its holdings in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after purchasing an additional 812 shares during the period. Metis Global Partners LLC grew its stake in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock worth $302,000 after acquiring an additional 860 shares during the period. Finally, Quadrant Capital Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after buying an additional 949 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TEVA shares. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Up 1.3 %

TEVA stock opened at $16.40 on Tuesday. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business has a 50 day moving average of $15.10 and a 200 day moving average of $17.48. The firm has a market cap of $18.59 billion, a PE ratio of -11.31, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.